AKT1 and B-cell chronic lymphocytic leukemia: This finding is ofinterest as the low dose of leukemia microvesicles (20 and 30 μg/mL) promotedsurvival and the higher dose (40 μg/mL) stimulated proliferation in healthy HSPCs.Ghosh et al. (2010)showed that B cell chronic lymphoblastic leukemia (B-CLL) derived microvesicles areable to activate and sustain activated AKT signaling in bone marrow stromal cells toproduce vascular endothelial growth factor (VEGF) as a survival factor for CLL Bcells.